Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FPR2 | P25090 | 9/20 | 0.40 |
| ▸ | RAB9A | P51151 | 5/20 | 0.39 |
| ▸ | NPC1 | O15118 | 3/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | FPR1 | P21462 | 1/20 | 0.33 |
| ▸ | TNIK | Q9UKE5 | 1/20 | 0.33 |
| ▸ | CNR1 | P21554 | 2/20 | 0.33 |
| ▸ | MAOA | P21397 | 1/20 | 0.32 |
| ▸ | MAOB | P27338 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3566120 | 0.99 | FPR2 (0.41) | FPR2RAB9ANPC1MEN1MAPT | |
| SCHEMBL3560271 | 0.92 | CYP1A2 (0.35) | FPR2MEN1MAPTHTTKMT2A | |
| SCHEMBL3561031 | 0.91 | CNR2 (0.35) | FPR2MEN1MAPTHTTKMT2A | |
| SCHEMBL5810278 | 0.85 | FPR2 (0.39) | FPR2RAB9ANPC1MEN1MAPT | |
| SCHEMBL3570284 | 0.84 | FPR2 (0.43) | FPR2RAB9ANPC1MEN1MAPT | |
| SCHEMBL3567223 | 0.84 | CNR1 (0.34) | FPR2RAB9AMEN1MAPTKMT2A | |
| SCHEMBL3560764 | 0.82 | SMN1; SMN2 (0.36) | FPR2RAB9ANPC1MEN1MAPT | |
| SCHEMBL5800502 | 0.81 | FPR2 (0.41) | FPR2RAB9ANPC1MEN1MAPT | |
| SCHEMBL5803484 | 0.81 | FPR2 (0.41) | FPR2RAB9ANPC1MEN1MAPT | |
| SCHEMBL3566171 | 0.80 | CNR1 (0.34) | RAB9ASMN1; SMN2ALDH1A1CNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7678913-B2 | Ureas as factor Xa inhibitors | PORTOLA PHARMACEUTICALS, INC. (US) | 2010-03-16 | — | — | US | claimed |
| US-20060160821-A1 | Ureas as factor Xa inhibitors | PORTOLA PHARMACEUTICALS, INC. (US) | 2006-07-20 | — | — | US | claimed |
| WO-2006063113-A2 | UREAS AS FACTOR XA INHIBITORS | PORTOLA PHARMACEUTICALS, INC. (US) | 2006-06-15 | — | — | WO | claimed |
| US-7678913-B2 | Ureas as factor Xa inhibitors | PORTOLA PHARMACEUTICALS, INC. (US) | 2010-03-16 | — | — | US | disclosed |
| US-20060160821-A1 | Ureas as factor Xa inhibitors | PORTOLA PHARMACEUTICALS, INC. (US) | 2006-07-20 | — | — | US | disclosed |
| WO-2006063113-A2 | UREAS AS FACTOR XA INHIBITORS | PORTOLA PHARMACEUTICALS, INC. (US) | 2006-06-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060160821-A1 | Ureas as factor Xa inhibitors | TFPI, F12, F11 | FPR2 2332/4885RAB9A 2958/4885NPC1 1325/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.